Skip to Content

The RNA Cure?

Alnylam Pharmaceuticals is poised to commercialize drugs made from RNA molecules.
November 1, 2003

It is being hailed as one of the biggest advances in biology in decades, one that could eventually lead to drugs for a wide range of diseases, from cancer to diabetes to AIDS. And one startup, Cambridge, MA-based Alnylam Pharmaceuticals, is in a particularly strong position to transform it into new pharmaceuticals.

In 1998, scientists discovered that RNA interference (RNAi)-a natural process in which small, double-stranded RNA molecules shut down the activity of particular genes-takes place in animals. For biomedical researchers, the implications were obvious; if you could selectively block genes involved in a disease, you could, in theory at least, stop it. Founded in 2002 by some of the pioneers of RNA interference research, Alnylam aims to synthesize small RNA molecules that could become the basis for a broad class of new drugs. So far, Alnylam has focused on cancer and metabolic diseases like diabetes. Its ambitious goal is to have a drug candidate in human testing by the end of 2005.

Keep Reading

Most Popular

This new data poisoning tool lets artists fight back against generative AI

The tool, called Nightshade, messes up training data in ways that could cause serious damage to image-generating AI models. 

Rogue superintelligence and merging with machines: Inside the mind of OpenAI’s chief scientist

An exclusive conversation with Ilya Sutskever on his fears for the future of AI and why they’ve made him change the focus of his life’s work.

The Biggest Questions: What is death?

New neuroscience is challenging our understanding of the dying process—bringing opportunities for the living.

Data analytics reveal real business value

Sophisticated analytics tools mine insights from data, optimizing operational processes across the enterprise.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.